After hours

Moderna, Inc.

MRNA · Nasdaq

$133.32-$44.6025.58%

At close: Aug 21, 6:32 AM

$129.78-$3.542.66%

· Vol 2.84M

: $174.38
: $53.23B
Open: —
: —
: $0.00 - $0.00
: $22.28 - $176.66
: —
: —
: 99.50M

Notable Price Movement

Weekly movement commentary will appear here once it has been generated for this company.

Stories & Analysis

Stocks Settle Lower as Rising Crude Prices Spur Inflation Fears

Barchart · 10h ago

Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead

The Motley Fool · 11h ago

Stocks Under Pressure as Bond Yields Climb on Inflation Fears

Barchart · 16h ago

Stocks Slip as Soaring Crude Prices Push Bond Yields Higher

Barchart · 17h ago

MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win

Zacks · 18h ago

S&P 500 Movers: MRNA, CF

BNK Invest · 18h ago

Is Cancer the Next Breakthrough for Moderna After COVID-19?

Zacks · 20h ago

Pre-Market Most Active for Aug 20, 2026 : HUIZ, IBIT, WMT, MRNA, CONL, MSTR, BMNR, BABA, NOK, CRCL, FCX, STLA

NASDAQ.com · 20h ago

Symbol: MRNA
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Intismeran autogene (intismeran; V940 or mRNA-4157) is a novel, potential first-in-class investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) jointly developed by Merck and Moderna. Intismeran is designed and produced using a patient's tumor sample to identify the unique mutational signature, or 'fingerprint,' of their cancer and generate an anti-tumor immune response. Each therapy consists of a synthetic mRNA coding for up to 34 neoantigens and is tailored to the unique biology of an individual patient's tumor. Upon administration, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system, a key step in generating specific T-cell responses against cancer cells. Individualized neoantigen therapies are designed to train and activate an anti-tumor immune response based on the unique mutational signature of a patient's tumor.

Key Issues

Bullish view

Net loss narrowed to $2.8 billion in FY2025 from $3.6 billion in FY2024, suggesting progress even as revenue declined.

Bearish view

Moderna remained deeply unprofitable in FY2025, while revenue fell to $1.9 billion from $3.2 billion, so the improvement may not represent a durable recovery.

Analyst Consensus

See all

Hold

21 analysts

$133

Current

—

Low

$48

Average

—

High

Average target implies -64.00% versus the current price.

Earnings History

BeatMissNo estimate

Peers

—

10.88M